%D8%B1%D9%88%D9%89_%D8%A7%D9%85._%D8%A7%D9%86%D8%AF%D9%8A%D8%B1%D8%B3%D9%88%D9%86%D8%B1%D9%88%DB%8C_%D9%85%D8%A7%D9%84%DA%A9%D9%88%D9%84%D9%85_%D8%A7%D9%86%D8%AF%D8%B1%D8%B3%D9%88%D9%86Roy_M._Anderson%D8%B1%D9%88%DB%8C_%D9%85%D8%A7%D9%84%DA%A9%D9%88%D9%84%D9%85_%D8%A7%D9%86%D8%AF%D8%B1%D8%B3%D9%88%D9%86Roy_M._AndersonQ7373091
about
P184
Modeling infectious disease dynamics in the complex landscape of global healthFactors that make an infectious disease outbreak controllableUpdated projections of future vCJD deaths in the UKCost and cost-effectiveness of soil-transmitted helminth treatment programmes: systematic review and research needsHow effective is school-based deworming for the community-wide control of soil-transmitted helminths?Modeling the interruption of the transmission of soil-transmitted helminths by repeated mass chemotherapy of school-age childrenInterrupting transmission of soil-transmitted helminths: a study protocol for cluster randomised trials evaluating alternative treatment strategies and delivery systems in KenyaRegulation and Stability of Host-Parasite Population Interactions: I. Regulatory ProcessesEconomic Considerations for Moving beyond the Kato-Katz Technique for Diagnosing Intestinal Parasites As We Move Towards Elimination.Can we reverse the HIV/AIDS pandemic with an expanded response?How Can Viral Dynamics Models Inform Endpoint Measures in Clinical Trials of Therapies for Acute Viral Infections?Understanding the within-host dynamics of influenza A virus: from theory to clinical implicationsFrequent travelers and rate of spread of epidemics.Mitigation strategies for pandemic influenza A: balancing conflicting policy objectives.Study of bias in antenatal clinic HIV-1 surveillance data in a high contraceptive prevalence population in sub-Saharan Africa.Critique of early models of the demographic impact of HIV/AIDS in sub-Saharan Africa based on contemporary empirical data from ZimbabweEstimating HIV incidence from age-specific prevalence data: comparison with concurrent cohort estimates in a study of male factory workers, Harare, Zimbabwe.Impact and process evaluation of integrated community and clinic-based HIV-1 control: a cluster-randomised trial in eastern Zimbabwe.Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settingsEvaluating the variation in the projected benefit of community-wide mass treatment for schistosomiasis: Implications for future economic evaluationsThe coverage and frequency of mass drug administration required to eliminate persistent transmission of soil-transmitted helminths.Sources of variability in the measurement of Ascaris lumbricoides infection intensity by Kato-Katz and qPCRThe importance of patient compliance in repeated rounds of mass drug administration (MDA) for the elimination of intestinal helminth transmission.Developing a mathematical model for the evaluation of the potential impact of a partially efficacious vaccine on the transmission dynamics of Schistosoma mansoni in human communities.Can chemotherapy alone eliminate the transmission of soil transmitted helminths?Identifying optimal threshold statistics for elimination of hookworm using a stochastic simulation model.The past matters: estimating intrinsic hookworm transmission intensity in areas with past mass drug administration to control lymphatic filariasis.Viral dynamics and anti-viral pharmacodynamics: rethinking in vitro measures of drug potency.Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong.Potential public health impact of imperfect HIV type 1 vaccines.The transmission dynamics of BSE and vCJD.Antiretroviral therapy to treat and prevent HIV/AIDS in resource-poor settings.Density-dependent effects on the weight of female Ascaris lumbricoides infections of humans and its impact on patterns of egg production.Review of foot-and-mouth disease virus survival in animal excretions and on fomites.Sources and Modes of Venereal Disease Infection in the Royal Canadian Air Force.Epidemiology, transmission dynamics and control of SARS: the 2002-2003 epidemic.Planning for smallpox outbreaks.Should the Goal for the Treatment of Soil Transmitted Helminth (STH) Infections Be Changed from Morbidity Control in Children to Community-Wide Transmission Elimination?Real-time estimates in early detection of SARSSARS-CoV antibody prevalence in all Hong Kong patient contacts
P50
Q24277713-07E6BC71-4E62-4D9B-BE55-94519B5F9E68Q24568031-637E25B0-4CE5-4366-9965-F11A3C47AAD5Q24799671-6C1AEB08-7DFB-4933-BA8C-DA3BA3E522C1Q26825338-02AA8BA9-2391-466D-AC4B-B1E09BEC5320Q28487150-A5EF48D0-1384-4DE6-B9F9-DAD08A06D464Q28542483-B598A37C-5C07-4237-B5AC-06C72CEB8664Q28610530-9FE93604-0BB8-41A2-997C-C20463A044C2Q29394656-D7928A54-421C-4492-90D3-6B5F26986066Q30236002-46AACC0A-07F0-4771-BD26-0588A268E813Q30331175-3315BE77-345E-468E-8BAE-B2DA235E81F0Q30357603-A0C3268D-9D08-493B-BB7D-15429A0F6FD4Q30357678-1AF60B13-D7CF-42F0-A2DA-D0DA14A5FBC7Q30367592-41E814DD-6E64-4065-8981-21424FB9F447Q30400112-23B253A9-8A6B-46DB-874D-E1E6CC63A77BQ30677198-5E74274B-6706-43FC-97F5-4728C751A4AFQ31123597-14FB377B-805A-4C60-BA29-1E5566BA9D6DQ31975741-7CC98CB7-5C0C-4D5D-8547-C0D1CCEB2B4CQ33280138-E9534F10-3BC5-4C69-99F6-5C369CCBFDC4Q33299456-4A8D23C2-DF73-431A-966F-FF8C1AEDA469Q33617862-4AB7579E-A7B7-4D30-9931-972366B03B12Q33624606-0CF315C2-927A-4862-839E-249856CF7D52Q33730865-AE82015D-B75B-462B-A1C3-CFE9CC6E34A5Q33792347-8C5E59BA-4582-4D23-A562-B1601A9532F3Q33808603-107979BD-8AB1-4611-8AC7-A900D36D5BCCQ33839193-204C9305-497A-4E65-89F7-6D7B1E774B0BQ33859219-E8E492ED-AC66-4B5F-A955-118BE298C40FQ33859236-63551BB3-B4DB-44BC-865F-160D2DF96356Q34134880-B4C3A6CF-D6B9-423E-925E-941BE9046027Q34202150-069768A0-2AC5-4747-8D5C-E5FBA15FBFCFQ34380779-9118B27C-F393-49B1-A273-24A2BD30AA7BQ34542865-A2B86F31-EC20-4167-B77B-5E9B6CE3F31FQ34714809-103525F3-C55C-4E9D-8F6F-5DB8777686EEQ34941948-791B0CE6-232D-4F17-A059-E2514A53608BQ35033073-F7E32526-9B2B-4EA2-B24F-16BA5B6278EAQ35057429-177F4A75-383B-4C44-AD8B-399F5C1C5F04Q35214004-BC4F4000-1D73-4843-A5F3-53B8FAC62CB9Q35561029-30FCA9C7-A3EF-4825-8AE3-D928F8B8C246Q35751194-5BB63E07-144F-4AA2-BAE2-6C5C4B9608C0Q35801637-6CB70A9B-4868-4DEC-855A-4289A77C1A07Q35872928-EF927764-B7F6-4B04-9350-0584381F33C6
P50
description
British expert on epidemiology
@en
Brits epidemioloog
@nl
name
Roy M. Anderson
@ast
Roy M. Anderson
@ca
Roy M. Anderson
@de
Roy M. Anderson
@en
Roy M. Anderson
@es
Roy M. Anderson
@fr
Roy M. Anderson
@hu
Roy M. Anderson
@it
Roy M. Anderson
@nl
Roy M. Anderson
@sl
type
label
Roy M. Anderson
@ast
Roy M. Anderson
@ca
Roy M. Anderson
@de
Roy M. Anderson
@en
Roy M. Anderson
@es
Roy M. Anderson
@fr
Roy M. Anderson
@hu
Roy M. Anderson
@it
Roy M. Anderson
@nl
Roy M. Anderson
@sl
altLabel
Anderson R
@en
Anderson R. M.
@en
Anderson R.
@en
Anderson RM
@en
Anderson
@en
R Anderson
@en
R M Anderson
@en
R. Anderson
@en
R. M. Anderson
@en
Roy Anderson
@en
prefLabel
Roy M. Anderson
@ast
Roy M. Anderson
@ca
Roy M. Anderson
@de
Roy M. Anderson
@en
Roy M. Anderson
@es
Roy M. Anderson
@fr
Roy M. Anderson
@hu
Roy M. Anderson
@it
Roy M. Anderson
@nl
Roy M. Anderson
@sl